Biomarker-guided therapies in heart failure: A forum for unified strategies

Mona Fiuzat, Christopher M. O'Connor, Francois Gueyffier, Alice M. Mascette, Nancy L. Geller, Alexandre Mebazaa, Adriaan A. Voors, Kirkwood F. Adams, Ileana L. Pina, Ludwig Neyses, Pieter Muntendam, G. Michael Felker, Bertram Pitt, Faiez Zannad, Michael R. Bristow

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The complexity of standard medical treatment for heart failure is growing, and such therapy typically involves 5 or more different medications. Given these pressures, there is increasing interest in harnessing cardiovascular biomarkers for clinical application to more effectively guide diagnosis, risk stratification, and therapy. It may be possible to realize an era of personalized medicine for heart failure treatment in which therapy is optimized and costs are controlled. The direct mechanistic coupling of biologic processes and therapies achieved in cancer treatment remains elusive in heart failure. Recent clinical trials and meta-analyses of biomarkers in heart failure have produced conflicting evidence. In this article, which comprises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris, France, we offer a brief overview of the background and rationale for biomarker testing in heart failure, describe opportunities and challenges from a regulatory perspective, and summarize current positions from government agencies in the United States and European Union.

Original languageEnglish (US)
Pages (from-to)592-599
Number of pages8
JournalJournal of Cardiac Failure
Volume19
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Heart Failure
Biomarkers
United States Government Agencies
Therapeutics
Precision Medicine
Biological Therapy
Paris
European Union
Treatment Failure
France
Meta-Analysis
Clinical Trials
Pressure
Costs and Cost Analysis
Neoplasms

Keywords

  • biologic markers
  • cardiovascular diseases
  • clinical trials
  • Pharmacogenetics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Fiuzat, M., O'Connor, C. M., Gueyffier, F., Mascette, A. M., Geller, N. L., Mebazaa, A., ... Bristow, M. R. (2013). Biomarker-guided therapies in heart failure: A forum for unified strategies. Journal of Cardiac Failure, 19(8), 592-599. https://doi.org/10.1016/j.cardfail.2013.05.012

Biomarker-guided therapies in heart failure : A forum for unified strategies. / Fiuzat, Mona; O'Connor, Christopher M.; Gueyffier, Francois; Mascette, Alice M.; Geller, Nancy L.; Mebazaa, Alexandre; Voors, Adriaan A.; Adams, Kirkwood F.; Pina, Ileana L.; Neyses, Ludwig; Muntendam, Pieter; Felker, G. Michael; Pitt, Bertram; Zannad, Faiez; Bristow, Michael R.

In: Journal of Cardiac Failure, Vol. 19, No. 8, 08.2013, p. 592-599.

Research output: Contribution to journalArticle

Fiuzat, M, O'Connor, CM, Gueyffier, F, Mascette, AM, Geller, NL, Mebazaa, A, Voors, AA, Adams, KF, Pina, IL, Neyses, L, Muntendam, P, Felker, GM, Pitt, B, Zannad, F & Bristow, MR 2013, 'Biomarker-guided therapies in heart failure: A forum for unified strategies', Journal of Cardiac Failure, vol. 19, no. 8, pp. 592-599. https://doi.org/10.1016/j.cardfail.2013.05.012
Fiuzat M, O'Connor CM, Gueyffier F, Mascette AM, Geller NL, Mebazaa A et al. Biomarker-guided therapies in heart failure: A forum for unified strategies. Journal of Cardiac Failure. 2013 Aug;19(8):592-599. https://doi.org/10.1016/j.cardfail.2013.05.012
Fiuzat, Mona ; O'Connor, Christopher M. ; Gueyffier, Francois ; Mascette, Alice M. ; Geller, Nancy L. ; Mebazaa, Alexandre ; Voors, Adriaan A. ; Adams, Kirkwood F. ; Pina, Ileana L. ; Neyses, Ludwig ; Muntendam, Pieter ; Felker, G. Michael ; Pitt, Bertram ; Zannad, Faiez ; Bristow, Michael R. / Biomarker-guided therapies in heart failure : A forum for unified strategies. In: Journal of Cardiac Failure. 2013 ; Vol. 19, No. 8. pp. 592-599.
@article{9a5dbe216a0747f8950d86bdac8475a8,
title = "Biomarker-guided therapies in heart failure: A forum for unified strategies",
abstract = "The complexity of standard medical treatment for heart failure is growing, and such therapy typically involves 5 or more different medications. Given these pressures, there is increasing interest in harnessing cardiovascular biomarkers for clinical application to more effectively guide diagnosis, risk stratification, and therapy. It may be possible to realize an era of personalized medicine for heart failure treatment in which therapy is optimized and costs are controlled. The direct mechanistic coupling of biologic processes and therapies achieved in cancer treatment remains elusive in heart failure. Recent clinical trials and meta-analyses of biomarkers in heart failure have produced conflicting evidence. In this article, which comprises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris, France, we offer a brief overview of the background and rationale for biomarker testing in heart failure, describe opportunities and challenges from a regulatory perspective, and summarize current positions from government agencies in the United States and European Union.",
keywords = "biologic markers, cardiovascular diseases, clinical trials, Pharmacogenetics",
author = "Mona Fiuzat and O'Connor, {Christopher M.} and Francois Gueyffier and Mascette, {Alice M.} and Geller, {Nancy L.} and Alexandre Mebazaa and Voors, {Adriaan A.} and Adams, {Kirkwood F.} and Pina, {Ileana L.} and Ludwig Neyses and Pieter Muntendam and Felker, {G. Michael} and Bertram Pitt and Faiez Zannad and Bristow, {Michael R.}",
year = "2013",
month = "8",
doi = "10.1016/j.cardfail.2013.05.012",
language = "English (US)",
volume = "19",
pages = "592--599",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "8",

}

TY - JOUR

T1 - Biomarker-guided therapies in heart failure

T2 - A forum for unified strategies

AU - Fiuzat, Mona

AU - O'Connor, Christopher M.

AU - Gueyffier, Francois

AU - Mascette, Alice M.

AU - Geller, Nancy L.

AU - Mebazaa, Alexandre

AU - Voors, Adriaan A.

AU - Adams, Kirkwood F.

AU - Pina, Ileana L.

AU - Neyses, Ludwig

AU - Muntendam, Pieter

AU - Felker, G. Michael

AU - Pitt, Bertram

AU - Zannad, Faiez

AU - Bristow, Michael R.

PY - 2013/8

Y1 - 2013/8

N2 - The complexity of standard medical treatment for heart failure is growing, and such therapy typically involves 5 or more different medications. Given these pressures, there is increasing interest in harnessing cardiovascular biomarkers for clinical application to more effectively guide diagnosis, risk stratification, and therapy. It may be possible to realize an era of personalized medicine for heart failure treatment in which therapy is optimized and costs are controlled. The direct mechanistic coupling of biologic processes and therapies achieved in cancer treatment remains elusive in heart failure. Recent clinical trials and meta-analyses of biomarkers in heart failure have produced conflicting evidence. In this article, which comprises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris, France, we offer a brief overview of the background and rationale for biomarker testing in heart failure, describe opportunities and challenges from a regulatory perspective, and summarize current positions from government agencies in the United States and European Union.

AB - The complexity of standard medical treatment for heart failure is growing, and such therapy typically involves 5 or more different medications. Given these pressures, there is increasing interest in harnessing cardiovascular biomarkers for clinical application to more effectively guide diagnosis, risk stratification, and therapy. It may be possible to realize an era of personalized medicine for heart failure treatment in which therapy is optimized and costs are controlled. The direct mechanistic coupling of biologic processes and therapies achieved in cancer treatment remains elusive in heart failure. Recent clinical trials and meta-analyses of biomarkers in heart failure have produced conflicting evidence. In this article, which comprises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris, France, we offer a brief overview of the background and rationale for biomarker testing in heart failure, describe opportunities and challenges from a regulatory perspective, and summarize current positions from government agencies in the United States and European Union.

KW - biologic markers

KW - cardiovascular diseases

KW - clinical trials

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=84881148332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881148332&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2013.05.012

DO - 10.1016/j.cardfail.2013.05.012

M3 - Article

C2 - 23910590

AN - SCOPUS:84881148332

VL - 19

SP - 592

EP - 599

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 8

ER -